Precision BioSciences (DTIL) shares were up nearly 27% in recent trading Friday, a day after its partner iEcure reported positive data on its in vivo gene insertion program and upgrade Friday from BMO Capital.
BMO Capital upgraded the company's stock to outperform from market perform, with a $34 price target.
iEcure reported positive data from the phase 1/2 study in the first patient treated with ECUR-506 for neonatal onset OTC deficiency, a hereditary metabolic disorder.
The treatment was well-tolerated overall, with only asymptomatic transaminitis noted at four weeks, which was managed with immunosuppressive therapy and resolved within another four weeks, it added.
Price: 5.70, Change: +1.20, Percent Change: +26.67
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。